PLX Earnings Date: Nov 12, 2026 (Estimated) — Protalix BioTherapeutics, Inc.
AMEX · Healthcare · Biotechnology
Updated
When is PLX's next earnings date?
Protalix BioTherapeutics, Inc. (PLX) is expected to report earnings on Thursday, November 12, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.02 on revenue of $12.4M.
How did PLX do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Protalix BioTherapeutics, Inc. posted EPS of $0.05 versus the -$0.01 estimate, a beat of 600.0%. Revenue was $19.9M against a $12.9M estimate. The stock's 1-day post-earnings move was +7.8%.
How much does PLX stock move after earnings?
PLX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.8% (up or down) in the day after earnings.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.01 | 0.05 | +600.00% | $19.9M | ✅ Beat | +7.82% | -3.70% | +12.35% |
| 2026-05-13 | Q1 2026 | -0.01 | 0.22 | +2300.00% | $33.8M | ✅ Beat | +1.05% | -0.52% | +7.33% |
| 2026-03-18 | Q4 2025 | 0.01 | -0.06 | -700.00% | $9.3M | ❌ Miss | -20.79% | -25.81% | -17.56% |
| 2025-11-13 | Q3 2025 | 0.05 | 0.03 | -40.00% | $17.7M | ❌ Miss | -9.81% | -17.29% | -16.36% |
| 2025-08-14 | Q2 2025 | 0.03 | 0.00 | -100.00% | $15.7M | ❌ Miss | -5.59% | -2.48% | +12.42% |
| 2025-03-17 | Q4 2024 | 0.07 | 0.09 | +28.57% | $18.2M | ✅ Beat | +9.38% | +11.16% | +16.96% |
| 2024-11-14 | Q3 2024 | 0.06 | 0.03 | -50.00% | $18.0M | ❌ Miss | +13.71% | +36.29% | +45.16% |
| 2024-08-14 | Q2 2024 | 0.02 | -0.03 | -250.00% | $13.5M | ❌ Miss | -10.58% | -8.56% | +1.92% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $19.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 99.7% | $19.8M | +28.4% | $35.1M | $10.0M | $15.4M | $17.7M |
| License and Service | 0.3% | $68K | -68.8% | $298K | $118K | $218K | $178K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.